Tenaya Therapeutics' long-term growth prospects are tied directly to the clinical success, regulatory clearance, and eventual commercialization of its proprietary pipeline of cardiovascular gene therapies and small-molecule drugs. Positive clinical data readouts from trials evaluating its lead candidates—such as TN-201 and TN-401—could position the enterprise as a pioneer in genetic heart disease treatment, while clinical setbacks or capital constraints present substantial corporate hurdles.